$0.4815
-0.0345[-6.69%]
At close: Apr 18
$0.4815
0[0.00%]
After Hours: 7:39PM EDT
Sangamo Therapeutics
(NASDAQ:SGMO)Sangamo Therapeutics Stock (NASDAQ:SGMO), Analyst Ratings, Price Targets, Predictions
Sangamo Therapeutics Inc has a consensus price target of $4.06, established from looking at the 27 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., RBC Capital, and HC Wainwright & Co. on March 19, 2024, March 14, 2024, and March 13, 2024. With an average price target of $3.33 between HC Wainwright & Co., RBC Capital, and HC Wainwright & Co., there's an implied 592.28% upside for Sangamo Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
RBC Capital
Truist Securities
Wells Fargo
Wedbush
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Sangamo Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 03/19/2024 | SGMO | Buy Now | Sangamo Therapeutics | $0.48 | 938.42% | HC Wainwright & Co. | Patrick Trucchio | $3 → $5 | Reiterates | Buy → Buy | Get Alert |
| 03/14/2024 | SGMO | Buy Now | Sangamo Therapeutics | $0.48 | 315.37% | RBC Capital | Luca Issi | → $2 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 03/13/2024 | SGMO | Buy Now | Sangamo Therapeutics | $0.48 | 523.05% | HC Wainwright & Co. | Patrick Trucchio | $3 → $3 | Maintains | Buy | Get Alert |
| 02/12/2024 | SGMO | Buy Now | Sangamo Therapeutics | $0.48 | 523.05% | HC Wainwright & Co. | Patrick Trucchio | → $3 | Reiterates | Buy → Buy | Get Alert |
| 02/06/2024 | SGMO | Buy Now | Sangamo Therapeutics | $0.48 | 523.05% | HC Wainwright & Co. | Patrick Trucchio | → $3 | Reiterates | Buy → Buy | Get Alert |
| 01/19/2024 | SGMO | Buy Now | Sangamo Therapeutics | $0.48 | 523.05% | HC Wainwright & Co. | Patrick Trucchio | → $3 | Reiterates | Buy → Buy | Get Alert |
| 11/07/2023 | SGMO | Buy Now | Sangamo Therapeutics | $0.48 | — | Truist Securities | Nicole Germino | — | Downgrade | Buy → Hold | Get Alert |
| 11/06/2023 | SGMO | Buy Now | Sangamo Therapeutics | $0.48 | 523.05% | HC Wainwright & Co. | Patrick Trucchio | $5 → $3 | Maintains | Buy | Get Alert |
| 11/06/2023 | SGMO | Buy Now | Sangamo Therapeutics | $0.48 | 107.68% | Wells Fargo | Jim Birchenough | → $1 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 11/03/2023 | SGMO | Buy Now | Sangamo Therapeutics | $0.48 | 315.37% | RBC Capital | Luca Issi | $6 → $2 | Downgrade | Outperform → Sector Perform | Get Alert |
| 08/15/2023 | SGMO | Buy Now | Sangamo Therapeutics | $0.48 | 1353.79% | Truist Securities | Nicole Germino | $8 → $7 | Maintains | Buy | Get Alert |
| 08/14/2023 | SGMO | Buy Now | Sangamo Therapeutics | $0.48 | 938.42% | HC Wainwright & Co. | Patrick Trucchio | → $5 | Reiterates | Buy → Buy | Get Alert |
| 08/11/2023 | SGMO | Buy Now | Sangamo Therapeutics | $0.48 | 1976.84% | Wedbush | Andreas Argyrides | $16 → $10 | Maintains | Outperform | Get Alert |
| 08/10/2023 | SGMO | Buy Now | Sangamo Therapeutics | $0.48 | 730.74% | Wells Fargo | Yanan Zhu | $5 → $4 | Maintains | Overweight | Get Alert |
| 08/09/2023 | SGMO | Buy Now | Sangamo Therapeutics | $0.48 | 1769.16% | Barclays | Gena Wang | $11 → $9 | Maintains | Overweight | Get Alert |
| 08/09/2023 | SGMO | Buy Now | Sangamo Therapeutics | $0.48 | 1146.11% | RBC Capital | Luca Issi | $8 → $6 | Maintains | Outperform | Get Alert |
| 05/10/2023 | SGMO | Buy Now | Sangamo Therapeutics | $0.48 | 1561.47% | Truist Securities | Nicole Germino | $16 → $8 | Maintains | Buy | Get Alert |
| 05/01/2023 | SGMO | Buy Now | Sangamo Therapeutics | $0.48 | 938.42% | HC Wainwright & Co. | Patrick Trucchio | $15 → $5 | Maintains | Buy | Get Alert |
| 04/28/2023 | SGMO | Buy Now | Sangamo Therapeutics | $0.48 | 211.53% | B of A Securities | Greg Harrison | $5 → $1.5 | Downgrade | Neutral → Underperform | Get Alert |
FAQ
What is the target price for Sangamo Therapeutics (SGMO)?
The latest price target for Sangamo Therapeutics (NASDAQ: SGMO) was reported by HC Wainwright & Co. on March 19, 2024. The analyst firm set a price target for $5.00 expecting SGMO to rise to within 12 months (a possible 938.42% upside). 19 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Sangamo Therapeutics (SGMO)?
The latest analyst rating for Sangamo Therapeutics (NASDAQ: SGMO) was provided by HC Wainwright & Co., and Sangamo Therapeutics reiterated their buy rating.
When was the last upgrade for Sangamo Therapeutics (SGMO)?
The last upgrade for Sangamo Therapeutics Inc happened on February 27, 2023 when Wedbush raised their price target to $16. Wedbush previously had a neutral for Sangamo Therapeutics Inc.
When was the last downgrade for Sangamo Therapeutics (SGMO)?
The last downgrade for Sangamo Therapeutics Inc happened on November 7, 2023 when Truist Securities changed their price target from N/A to N/A for Sangamo Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Sangamo Therapeutics (SGMO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sangamo Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sangamo Therapeutics was filed on March 19, 2024 so you should expect the next rating to be made available sometime around March 19, 2025.
Is the Analyst Rating Sangamo Therapeutics (SGMO) correct?
While ratings are subjective and will change, the latest Sangamo Therapeutics (SGMO) rating was a reiterated with a price target of $3.00 to $5.00. The current price Sangamo Therapeutics (SGMO) is trading at is $0.48, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.